NCT06559644View on ClinicalTrials.gov

Hema-NeoTIL01 Cell Infusion Therapy in Relapsed/Refractory Acute Leukemia

EARLY_PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 1, 2024

Primary Completion Date

September 1, 2026

Study Completion Date

December 1, 2026

Conditions

Leukemia, Myeloid, AcuteB-cell Acute Lymphoblastic Leukemia

Interventions

BIOLOGICAL

Hema-NeoTIL01

Patients will receive intravenous infusion of Hema-NeoTIL01, which is a highly specific tumor infiltrating lymphocyte (TIL) product derived from patients' bone marrow or peripheral blood, expanded ex vivo through antigen presentation.

Trial Locations (1)

215006

The First Affiliated Hospital of Soochow University, Suzhou

All Listed Sponsors

lead

The First Affiliated Hospital of Soochow University

OTHER

NCT06559644 - Hema-NeoTIL01 Cell Infusion Therapy in Relapsed/Refractory Acute Leukemia | Biotech Hunter | Biotech Hunter